Key Highlights

  • LSE:IMM shares are up 5.87% on 2 September 2026, putting ImmuPharma among the notable healthcare gainers being watched by investors.
  • The company's most recent major development was the appointment of Kymos Group as the bioanalytical CRO partner for Kapiglucagon in August 2026.
  • Kapiglucagon is being developed as a proprietary glucagon prodrug for Type 1 diabetes, with the company pursuing an accelerated development strategy.
  • ImmuPharma has also selected Thermo Fisher Scientific as the drug-product Manufacturing and development partner for Kapiglucagon.
  • Bachem has been appointed as the API manufacturing partner, creating an increasingly complete manufacturing and development infrastructure around Kapiglucagon.
  • The company is evaluating a potential 505(b)(2) regulatory pathway in the United States, subject to regulatory confirmation.
  • ImmuPharma's established P140 programme, also known as Lupuzor, remains a core part of the company's long-term valuation story.
  • The company completed a £6.47 million fundraising in April 2026, materially strengthening its financial position compared with the end of 2025.
  • The stock remains highly speculative because clinical development, regulatory outcomes, financing and future partnering arrangements can materially affect valuation.

Why Is ImmuPharma Stock in Focus Today?

ImmuPharma plc has become increasingly interesting to investors after LSE:IMM gained 5.87% on 2 September 2026.

The company is a specialist biotechnology Business developing peptide-based medicines in areas where there is substantial unmet medical need.

Its Investment story has historically centred on P140, the company's lead autoimmune programme associated with Lupuzor.

However, the 2026 story is becoming broader.

Kapiglucagon has emerged as an important second development programme, and ImmuPharma has made a series of announcements designed to move the asset towards regulatory and clinical development.

The latest major milestone came in August, when the company selected Kymos Group as its bioanalytical development partner.

That followed the selection of Bachem for API manufacturing and Thermo Fisher for drug-product development and manufacturing.

The sequence of appointments is significant because it indicates that Kapiglucagon is moving from an earlier development concept towards a more structured pharmaceutical-development programme.

ImmuPharma Shares Rise 5.87% on 2 September 2026

The headline move is a 5.87% gain in LSE:IMM on 2 September 2026.

There is no indication that a single same-day corporate announcement accounts for the entire move.

Instead, today's buying interest needs to be viewed in the context of the company's increasingly active development pipeline.

The most recent significant catalyst was the August appointment of Kymos Group.

Before that, investors had seen the company appoint major specialist partners for the manufacturing and development of Kapiglucagon.

These developments have helped create a more visible pathway towards the next stages of pharmaceutical development.

For a small biotechnology company, such milestones can have an outsized effect on investor sentiment because the valuation is heavily influenced by expectations surrounding future clinical and commercial outcomes.

Kapiglucagon Has Become a Major 2026 Catalyst

Kapiglucagon is one of the most important developments in the current ImmuPharma story.

The programme centres on a proprietary glucagon prodrug designed to address some of the limitations associated with native glucagon.

The company is developing it for potential applications related to Type 1 diabetes, including possible use in glucagon-based therapeutic approaches.

The strategic attraction is that glucagon has an established role in managing low blood glucose, but conventional glucagon formulations have limitations involving properties such as solubility and formulation stability.

ImmuPharma believes its proprietary approach could provide a differentiated product opportunity.

However, the asset remains in development.

That means investors should distinguish between the potential commercial opportunity and an approved pharmaceutical product.

Kapiglucagon still has to progress through development and regulatory stages before its commercial potential can be established.

Kymos Partnership Moves the Programme Forward

The latest major catalyst came on 10 August 2026, when ImmuPharma selected Kymos Group as its bioanalytical contract research organisation partner.

Kymos will support the development and validation of regulated bioanalytical methods for Kapiglucagon.

Its work is intended to support both non-clinical development and the future Phase 1 clinical programme.

This is an important technical step because high-quality bioanalytical methods are necessary to generate reliable data during pharmaceutical development.

The appointment also follows a competitive selection process, giving investors another indication that ImmuPharma is building a specialist development infrastructure around the asset.

Thermo Fisher Adds Another Major Development Partner

In July, ImmuPharma selected Thermo Fisher Scientific as its drug-product contract development and manufacturing organisation for Kapiglucagon.

This was described as an important chemistry, manufacturing and controls milestone for the programme.

The appointment is expected to support pharmaceutical development and preparations required for the next regulatory stages.

For investors, the significance is not simply the name of the partner.

It is the fact that Kapiglucagon now has dedicated partners across several important parts of the development chain.

This can potentially improve execution and provide access to specialised manufacturing and development capabilities.

It also means the programme is progressing beyond laboratory-level development towards a more formal drug-development pathway.

Bachem Strengthens the Kapiglucagon Manufacturing Strategy

ImmuPharma appointed Bachem as the API manufacturing partner for Kapiglucagon in June 2026.

Bachem specialises in peptide and oligonucleotide development and manufacturing.

For a peptide-based programme, establishing a capable API manufacturing partner is a major component of the development process.

The appointment complements the later selection of Thermo Fisher for drug-product work.

Together, these partnerships provide ImmuPharma with a more developed manufacturing framework as it advances Kapiglucagon.

This is particularly relevant because manufacturing and chemistry requirements can become major development bottlenecks for emerging biotechnology companies.

Potential 505(b)(2) Pathway Is Being Evaluated

One of the most interesting elements of the Kapiglucagon strategy is the company's evaluation of a possible 505(b)(2) regulatory pathway in the United States.

The potential attraction is that such a pathway can, where appropriate and accepted by regulators, Leverage certain existing information relating to an already established active ingredient rather than requiring every element of development to be generated from scratch.

For ImmuPharma, this could potentially create a more streamlined development strategy.

However, the pathway remains subject to regulatory discussions and confirmation.

Investors should therefore treat it as a potential efficiency rather than a guaranteed shortcut.

Regulatory requirements can change depending on the product, formulation, intended use and supporting data.

Funding Position Has Improved

Funding is another important reason investors are watching LSE:IMM.

ImmuPharma reported a loss of approximately £1.8 million for 2025, compared with a £2.5 million loss in 2024.

Research and development spending increased modestly to approximately £1.3 million.

At the end of 2025, the company had approximately £1.4 million of cash, compared with £0.2 million a year earlier.

More importantly, ImmuPharma completed a £6.47 million fundraising in April 2026, consisting of a £6 million subscription and a £0.47 million retail offer.

The stronger funding position provides greater capacity to progress Kapiglucagon and its other programmes.

For investors, however, the key question is how quickly that Capital is consumed and whether future development milestones require additional funding.

P140 Remains the Core Long-Term Value Driver

Despite the increased attention surrounding Kapiglucagon, ImmuPharma's P140 programme remains central to the company's long-term investment case.

P140, also known as Lupuzor or forigerimod, is being developed as a peptide-based treatment approach for autoimmune disease.

The company's broader P140 platform is designed around the concept of restoring immune balance rather than simply suppressing the immune system.

That creates a potentially differentiated proposition in autoimmune medicine.

The company has also been developing a companion diagnostic strategy designed to identify patients who may respond particularly well to P140.

This precision-medicine approach could potentially improve the commercial and clinical positioning of the programme if supported by future clinical evidence.

University of Murcia Research Adds Scientific Interest

Another development attracting attention has been research from the University of Murcia relating to P140.

The research explored potential applications of the P140 peptide in glioblastoma, an aggressive form of brain cancer.

The work is early-stage and should not be interpreted as evidence that P140 is an established treatment for cancer.

Nevertheless, additional scientific research around a company's proprietary platform can broaden investor interest by highlighting potential applications beyond the lead indication.

For ImmuPharma, the immediate focus remains on advancing its established development programmes rather than assuming that experimental research will translate directly into commercial products.

Why Investors Are Watching LSE:IMM

The reason investors are paying attention to ImmuPharma is that several potential catalysts are now developing simultaneously.

Kapiglucagon is progressing through an increasingly structured development programme.

Manufacturing partners have been appointed.

A specialist bioanalytical partner has been selected.

Funding has been strengthened.

P140 remains the company's core autoimmune technology platform.

This creates multiple potential valuation drivers.

The challenge is that most of them remain dependent on future execution.

For biotechnology investors, this creates both the attraction and the risk.

Successful clinical or regulatory developments can result in substantial valuation changes, while disappointing data or delays can have the opposite effect.

What Could Drive ImmuPharma Stock Higher?

Several developments could potentially support LSE:IMM in the coming months.

Progress with Kapiglucagon's IND-enabling work would be important.

Further regulatory clarity around the potential US pathway could also improve investor visibility.

Progress towards Phase 1 clinical development would represent another major milestone.

For P140, investors will be looking for evidence of commercial progress, partnering discussions, regulatory development and further scientific validation.

A licensing or strategic partnership could potentially be particularly important because it could provide external validation and potentially reduce the financial burden on ImmuPharma.

The Main Risks Facing LSE:IMM

The principal risk is clinical.

Kapiglucagon has not yet demonstrated commercial efficacy in late-stage human trials.

P140 also remains a development-stage asset.

There is therefore no guarantee that either programme will ultimately become a successful commercial medicine.

Regulatory risk is another major consideration.

Even an attractive scientific proposition can encounter delays, additional testing requirements or regulatory obstacles.

Funding is also important.

The April fundraising materially improved the company's financial resources, but biotechnology development can consume significant capital.

Additional financing may eventually be required depending on development speed and costs.

Shareholder dilution therefore remains a risk.

ImmuPharma Outlook for the Rest of 2026

The second half of 2026 could be an important period for ImmuPharma.

The company has established a network of specialist partners around Kapiglucagon and is now working through the technical and regulatory requirements needed to advance the programme.

Investors are likely to focus on development milestones rather than conventional Revenue or Earnings growth because ImmuPharma remains a development-stage biotechnology company.

The key question is whether management can convert its improved funding position and newly established development infrastructure into measurable progress towards clinical development.

If it can, the investment narrative could strengthen considerably.

What Investors Should Watch Next

Investors following LSE:IMM should watch for further Kapiglucagon development updates, progress on bioanalytical work, manufacturing activities, regulatory discussions, IND-enabling preparations and the eventual transition towards human clinical testing.

P140 remains equally important.

Any progress towards licensing, partnerships, clinical development or additional validation could materially affect market expectations.

The company's cash position and rate of expenditure should also remain closely monitored.

Bottom Line on ImmuPharma Stock

The 5.87% rise in LSE:IMM on 2 September 2026 comes at an interesting stage in ImmuPharma's development.

The company has moved aggressively to build a development infrastructure for Kapiglucagon, with Bachem, Thermo Fisher and Kymos Group now involved across different stages of the programme.

At the same time, P140 remains the company's principal long-term autoimmune asset.

The April 2026 fundraising has provided additional financial resources, while the narrowing annual loss indicates some improvement in the reported financial profile.

The opportunity is significant if ImmuPharma can successfully progress its drug candidates towards clinical development, regulatory approval and eventual commercialisation.

But the risk remains equally significant.

LSE:IMM is a speculative biotechnology stock whose valuation depends heavily on future clinical, regulatory, financing and partnering outcomes.

For investors watching today's 5.87% gain, the key issue is therefore not simply the daily share-price move, but whether the company's recent development milestones translate into real clinical progress and ultimately commercial value.